Xention Overview
- Year Founded
-
2002
- Status
-
Out of Business
- Employees
-
13
- Latest Deal Type
-
Out of Business
Xention General Information
Description
Developer of novel therapies intended to improve the treatment of atrial fibrillation. The company's therapies develop drug candidates that modulate two novel but well-characterized, ion channels to develop breakthrough products in this area of huge unmet medical need, enabling healthcare sector to use channel-modulating drugs for the treatment of atrial fibrillation, overactive bladder, pain, and autoimmune diseases.
Contact Information
Website
www.xention.comCorporate Office
- 38 High Street
- Newmarket
- Suffolk CB8 8LB
- England, United Kingdom
Corporate Office
- 38 High Street
- Newmarket
- Suffolk CB8 8LB
- England, United Kingdom
Xention Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Out of Business | 01-Jan-2023 | Completed | Out of Business | |||
| 9. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 8. Later Stage VC | 01-Mar-2015 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series D) | 18-Oct-2012 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series D) | 23-Nov-2010 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 25-Jun-2010 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 31-Mar-2008 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 18-Jul-2005 | Completed | Startup | |||
| 2. Early Stage VC | 10-Sep-2003 | $6.34M | $12.6M | Completed | Startup | |
| 1. Early Stage VC | 01-Aug-2002 | $6.24M | $6.24M | Completed | Startup |
Xention Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| D Preferred |
Xention Comparisons
Industry
Financing
Details
Xention Competitors (101)
One of Xention’s 101 competitors is Enterprise Therapeutics, a Venture Capital-Backed company based in Brighton, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Apeptico | Formerly VC-backed | Vienna, Austria | ||||
| Aquinnah | Venture Capital-Backed | Cambridge, MA | ||||
| Mighty Therapeutics | Private Equity-Backed | Needham, MA |
Xention Patents
Xention Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-201215284-D0 | Compounds | Inactive | 28-Aug-2012 | ||
| GB-201214250-D0 | Compounds | Inactive | 09-Aug-2012 | ||
| GB-201119703-D0 | Compounds | Inactive | 15-Nov-2011 | ||
| GB-201119745-D0 | Compounds | Inactive | 15-Nov-2011 | ||
| US-20140357662-A1 | Thieno (2,3 - c) pyrazoles for use as potassium channel inhibitors | Inactive | 15-Nov-2011 | C07D495/04 |
Xention Signals
Xention FAQs
-
When was Xention founded?
Xention was founded in 2002.
-
Where is Xention headquartered?
Xention is headquartered in Suffolk, United Kingdom.
-
What is the size of Xention?
Xention has 13 total employees.
-
What industry is Xention in?
Xention’s primary industry is Drug Discovery.
-
Is Xention a private or public company?
Xention is a Private company.
-
What is Xention’s current revenue?
The current revenue for Xention is .
-
How much funding has Xention raised over time?
Xention has raised $53.3M.
-
Who are Xention’s competitors?
Enterprise Therapeutics, AnTolRx, Apeptico, Aquinnah, and Mighty Therapeutics are some of the 101 competitors of Xention.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process